FibroBiologics financials
$1.31−3.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$16.6M | -$13.7M |
| Net income | -$18.6M | -$11.2M |
| Net margin | — | — |
| Diluted EPS | $-8.40 | $-6.80 |
| EBITDA | -$15.8M | -$13.2M |
| Operating cash flow | -$16.4M | -$11.9M |
| Free cash flow | -$16.7M | -$12.1M |
| Diluted shares | 2.2M | 1.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $4.9M | $14.0M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $9.2M |
| Total assets | $9.6M | $16.4M |
| Total liabilities | $3.5M | $13.7M |
| Shareholders' equity | $6.2M | $2.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology